右美托咪定在特殊人群中的药代动力学研究进展  

Progress in pharmacokinetics of dexmedetomidine in special populations

作　　者：章冉冉[1,2] 阳国平[2] 裴奇[3] 彭金富[1,2] 阳喜定[1,2] 刘莉[1,2] 

机构地区：[1]中南大学药学院,长沙410013 [2]中南大学湘雅三医院临床药理中心,长沙410013 [3]中南大学湘雅三医院药剂科,长沙410013

出　　处：《中国临床药理学杂志》2014年第7期650-652,共3页The Chinese Journal of Clinical Pharmacology

基　　金：国家"重大新药创制"科技重大专项基金资助项目(2012ZX09303014-001);国家自然科学基金资助项目(81302851);湖南省自然基金重点资助项目(11JJ2054);湖南省卫生厅课题基金资助项目(132013-028)

摘　　要：右美托咪定是新型高效、高选择性的α2肾上腺素受体激动剂,具有镇痛及剂量依耐性镇静作用,呼吸抑制作用弱,是目前唯一的一种可唤醒的镇静药。但右美托咪定个体差异较大,导致其剂量较难控制,特别表现在特殊人群的应用中。本文对右美托咪定在儿童、老年人以及肝肾功能不全等特殊人群中的药代动力学研究的最新进展进行综述。Dexmedetomidine , a strong potent and highly selective α2 -adrenoceptor agonist , has an analgesic and dose -dependent sedative property with minimal effects on respiratory depression.It is the only tranquilizing drug which can be arousal currently and is also widely used in clinical applications because of its special pharmacologic characteris-tics.However, dexmedetomidine has large individual differences which made the control of administration dosage more difficult , especially in special populations.So this review article summarized the latest litera-tures about pharmacokinetics of dexmedetomidine in children , the elder-ly , hepatic and renal insufficiency patients and other special populations.

关 键 词：右美托咪定 肝功能不全 肾功能不全 药代动力学 

分 类 号：R969.1[医药卫生—药理学]